---
schema_version: "secwatch.filing_event.v1"
accession: "0001520138-24-000105"
form_type: "8-K"
ticker: "BIVI"
cik: "0001580149"
company_name: "BIOVIE INC."
filed_at: "2024-03-11T23:59:59+00:00"
generated_at: "2026-06-04T23:50:22.541358+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# BioVie updates pipeline; plans Phase 2b PD trial summer 2024, delays AD Phase 3 to 2025

## Summary
- Raised $18.8M net ($21M gross) in equity financing to fund near-term priorities.
- Phase 2b monotherapy trial of NE3107 in Parkinson's planned for late summer 2024; 100–150 patients.
- Phase 3 Alzheimer's trial postponed to early 2025 to use once-daily NE3107 formulation.
- BIV201 Phase 3 in ascites delayed pending partnership; FDA guidance received.
- Previous NE3107 data showed 68% slowing on CDR-SB in AD and improved non-motor symptoms in PD.

## SEC filing metadata
- accession: 0001520138-24-000105
- form_type: 8-K
- ticker: BIVI
- cik: 0001580149
- company_name: BIOVIE INC.
- filed_at: 2024-03-11T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1580149/000152013824000105/0001520138-24-000105-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1580149/000152013824000105/bivi-20240311_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001520138-24-000105
- JSON: https://secwatch.observer/filing/0001520138-24-000105.json
- Plain text: https://secwatch.observer/filing/0001520138-24-000105.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.